Print

Infinity Pharmaceuticals Inc. (INFI) Reports Updated Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 in Chronic Lymphocytic Leukemia at American Society of Clinical Oncology Annual Meeting  
6/3/2013 7:13:17 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced updated Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), a potentially fatal hematologic malignancy, or blood cancer. Data from the study showed that IPI-145 was well tolerated, with a rapid onset of clinical activity.

Help employers find you! Check out all the jobs and post your resume.

//-->